18/10/2020 USP-NF Azithromycin

Printed on: Sun Oct 18 2020, 14:00:16 pm

Printed by: Shruti Kharidia
O cial Status: Currently O cial on 18-Oct-2020
O cial Date: O cial as of 1-May-2020
Document Type: USP
DocId: 1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US
Printed from: https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US
© 2020 USPC

Azithromycin

USP Amitriptyline Hydrochlo

USP Amitriptyline Related Co

A RS

USP Amitriptyline Related Co

B RS
USP Nortriptyline Hydrochlo

EMAIL REFERENCE STANDARDS

C38H72N2O12 748.98
C38H72N2O12 · H2O 767.00
C38H72N2O12 · 2H2O 785.02
1-Oxa-6-azacyclopentadecan-15-one, 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, [2R-

L
(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)];
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
IA
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one;
9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A
Anhydrous [83905-01-5].
Monohydrate [121470-24-4].
Dihydrate [117772-70-0].
IC

DEFINITION
Azithromycin is anhydrous or contains 1 or 2 molecules of water of hydration. It contains the equivalent of NLT 945 µg/mg and NMT
1030 µg/mg of azithromycin (C38H72N2O12), calculated on the anhydrous basis.
FF

IDENTIFICATION
Change to read:
• A. ▲SPECTROSCOPIC IDENTIFICATION TESTS 〈197〉, Infrared Spectroscopy: 197K▲ (CN 1-MAY-2020): If a difference appears in the IR spectra of the
analyte and the Standard, dissolve equal portions of the test specimen and the USP Reference Standard in equal volumes of methanol.
Evaporate the solutions to dryness on a water bath, and dry at 80° for 30 min under vacuum. Perform the test on the residues.
O

• B. The retention time of the azithromycin peak of the Sample solution corresponds to that of the Standard solution, as obtained in the
Assay.

ASSAY
• PROCEDURE
Solution A: 10 M potassium hydroxide
Solution B: 6.7 g/L of dibasic potassium phosphate, adjusted with Solution A to a pH of 11.0
Solution C: 6.7 g/L of dibasic potassium phosphate, adjusted with phosphoric acid to a pH of 8.0
Mobile phase: Acetonitrile and Solution B (60:40)
Diluent: Acetonitrile and Solution C (60:40)
System suitability solution: 0.5 mg/mL each of USP Azithromycin RS and USP Azaerythromycin A RS prepared as follows. Dissolve
USP Azithromycin RS and USP Azaerythromycin A RS rst in acetonitrile, using 5% of the nal volume, and then dilute with Diluent to
volume.
Standard solution: 0.53 mg/mL of USP Azithromycin RS prepared as follows. Dissolve USP Azithromycin RS rst in acetonitrile, using
2% of the nal volume, and then dilute with Diluent to volume.
Sample solution: 0.53 mg/mL of Azithromycin prepared as follows. Dissolve Azithromycin rst in acetonitrile, using 2% of the nal
volume, and then dilute with Diluent to volume.

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 1/8
18/10/2020 USP-NF Azithromycin
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 210 nm
Column: 4.6-mm × 25-cm; 5-µm packing L67
Column temperature: 40°
Flow rate: 1 mL/min
Injection volume: 10 µL
System suitability
Samples: System suitability solution and Standard solution
[ NOTE— The relative retention times for azaerythromycin A and azithromycin are 0.7 and 1.0, respectively.]
Suitability requirements
Resolution: NLT 3.0 between azaerythromycin A and azithromycin, System suitability solution
Tailing factor: 0.8–1.5 for azithromycin, Standard solution
Relative standard deviation: NMT 1.10% for azithromycin, Standard solution
Analysis
Samples: Standard solution and Sample solution
Calculate the quantity, in µg, of azithromycin (C38H72N2O12) in each milligram of Azithromycin taken:

Result = (rU/rS) × (CS/CU) × P

rU = peak response from the Sample solution

rS = peak response from the Standard solution

CS = concentration of USP Azithromycin RS in the Standard solution

L
CU = concentration of Azithromycin in the Sample solution
IA
P = potency of USP Azithromycin RS (µg/mg of azithromycin)

Acceptance criteria: 945–1030 µg/mg on the anhydrous basis

IMPURITIES
• RESIDUE ON IGNITION 〈281〉: NMT 0.3%, moistening the charred residue with 2 mL of nitric acid and 5 drops of sulfuric acid
IC

Delete the following:

▲• ORGANIC IMPURITIES, PROCEDURE 1

Use Organic Impurities, Procedure 1 when the impurity pro le includes erythromycin A oxime and erythromycin A iminoether.
Use water that has a resistivity of NLT 18 Mohm-cm.
FF

Solution A: 20 mM dibasic potassium phosphate

Mobile phase: Acetonitrile and Solution A (250:750). Adjust with 5 M potassium hydroxide to a pH of 10.55 ± 0.05.
Standard stock solution: 45 µg/mL of USP Desosaminylazithromycin RS, 105 µg/mL of USP N-Demethylazithromycin RS, 150 µg/mL
of USP Azaerythromycin A RS, and 160 µg/mL of USP Azithromycin RS in acetonitrile. Sonicate as necessary to dissolve.
Standard solution: 0.9 µg/mL of USP Desosaminylazithromycin RS, 2.1 µg/mL of USP N-Demethylazithromycin RS, 3.0 µg/mL of USP
O

Azaerythromycin A RS, and 3.2 µg/mL of USP Azithromycin RS from the Standard stock solution in Mobile phase
Sample solution: 0.33 mg/mL of Azithromycin prepared as follows. Transfer a suitable amount of Azithromycin to a suitable
volumetric ask. Add acetonitrile, using 5% of the nal volume, and sonicate as necessary to dissolve. Dilute with Mobile phase to
volume.
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: Amperometric electrochemical
Detector type: Dual glassy carbon electrodes
Detector mode: Oxidative screen mode
Detector settings
Electrode 1: +0.70V
Electrode 2: +0.82V
Column: 4.6-mm × 15-cm; 3-µm packing L49
Temperatures
Detector preheater: 28°
Autosampler: 5°
https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 2/8
18/10/2020 USP-NF Azithromycin

Flow rate: 1 mL/min

Injection volume: 50 µL
System suitability
Sample: Standard solution
Suitability requirements
Resolution: NLT 3.0 between azithromycin and azaerythromycin A
Tailing factor: NMT 2.0 for azithromycin; NMT 2.5 for N-demethylazithromycin
Relative standard deviation: NMT 10.0% for azithromycin, azaerythromycin A, N-demethylazithromycin, and
desosaminylazithromycin
Analysis
Samples: Standard solution and Sample solution
Record the Sample solution chromatograms for NLT 3.3 times the retention time of the azithromycin peak.
Calculate the percentages of desosaminylazithromycin, N-demethylazithromycin, and azaerythromycin A in the portion of
Azithromycin taken:

Result = (rU/rS) × (CS/CU) × F × 100

rU = peak area of the relevant analyte from the Sample solution

rS = peak area of the relevant analyte from the Standard solution

CS = concentration of the appropriate USP Reference Standard in the Standard solution (µg/mL)

CU = concentration of the Sample solution (mg/mL)

F = conversion factor, 0.001 mg/µg

L
Calculate the percentages of other related substances in the portion of Azithromycin taken:

Result = (rU/rS) × (CS/CU) × F × 100

IA
rU = peak area of each additional impurity from the Sample solution

rS = peak area of the azithromycin peak from the Standard solution

CS = concentration of USP Azithromycin RS in the Standard solution (µg/mL)

IC

CU = concentration of the Sample solution (mg/mL)

F = conversion factor, 0.001 mg/µg

FF

Acceptance criteria: See Table 1.

Table 1

Name Relative Retention Time Acceptance Criteria, NMT (%)

O

Erythromycin A iminoethera 0.19 0.5

Desosaminylazithromycinb 0.29 0.3

Erythromycin A oximec 0.37 0.5

N-Demethylazithromycind 0.49 0.7

Azaerythromycin Ae 0.80 1.0

Azithromycin 1.0 —

3-Deoxyazithromycin (azithromycin B)f 2.33 1.0

Total impurities — 3.0

▲ (USP 1-May-2019)

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 3/8
18/10/2020 USP-NF Azithromycin
a
  (3R,4R,5S,6R,9R,10S,11S,12R,13S,15R,Z)-12-[[3,4,6-Trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-6-ethyl-4,5-dihydroxy-
10-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-3,5,9,11,13,15-hexamethyl-7,16-dioxa-2-
azabicyclo[11.2.1]hexadec-1-en-8-one.
b 
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
dimethylamino-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
c 
(3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-[[3,4,6-Trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-14-ethyl-7,12,13-
trihydroxy-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-10-(hydroxyimino)-3,5,7,9,11,13-
hexamethyloxacyclotetradecan-2-one.
d 
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-methylamino-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-
15-one.
e 
9-Deoxo-9a-aza-9a-homoerythromycin A; 6-Demethylazithromycin.
f  (2R,3R,4S,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-4,10-dihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.

Change to read:
• ORGANIC IMPURITIES
▲
▲ (USP 1-May-2019)
Solution A: 1.8 mg/mL of anhydrous dibasic sodium phosphate in water. Adjust with 1 N sodium hydroxide or 10% phosphoric acid to
a pH of 8.9.
Solution B: Acetonitrile and methanol (3:1)
Solution C: 1.73 mg/mL of monobasic ammonium phosphate. Adjust with ammonia TS to a pH of 10.0 ± 0.05.
Solution D: Methanol, acetonitrile, and Solution C (7:6:7)
Mobile phase: See Table 1.

L
Table 1
IA
Time (min) Solution A (%) Solution B (%)

0 50 50
IC

25 45 55

30 40 60

80 25 75
FF

81 50 50

93 50 50
O

System suitability solution: 0.0165 mg/mL of USP Azithromycin Related Compound F RS and 0.027 mg/mL of USP
Desosaminylazithromycin RS in Solution D
Standard solution: 86 µg/mL of USP Azithromycin RS in Solution D
Sample solution: 8.6 mg/mL of Azithromycin in Solution D
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 210 nm
Column: 4.6-mm × 25-cm; 5-µm packing L1
Column temperature: 60°
Flow rate: 1 mL/min
Injection volume: 50 µL
System suitability
Samples: System suitability solution and Standard solution
Suitability requirements
Peak-to-valley ratio: NLT 1.4, System suitability solution Calculate the peak-to-valley ratio:

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 4/8
18/10/2020 USP-NF Azithromycin
Result = HP/HV

HP = height above the baseline of the desosaminylazithromycin peak

HV = height above the baseline of the lowest point of the curve separating the desosaminylazithromycin and azithromycin
related compound F peaks

Tailing factor: 0.8–1.5, Standard solution

Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of each impurity in the portion of Azithromycin taken:

Result = (rU/rS) × (CS/CU) × P × F1 × (100/F2)

rU = peak response of each impurity from the Sample solution

rS = peak response of azithromycin from the Standard solution

CS = concentration of USP Azithromycin RS in the Standard solution (mg/mL)

CU = concentration of Azithromycin in the Sample solution (mg/mL)

P = potency of USP Azithromycin RS (µg/mg of azithromycin)

F1 = conversion factor, 0.001 mg/µg

F2 = relative response factor (see Table 2)

L
Acceptance criteria: See Table 2. Disregard peaks eluting before azithromycin N-oxide and after 3-deoxyazithromycin (azithromycin
B). Disregard peaks with a response less than 0.1 times the response of the azithromycin peak in the Standard solution (0.1%).
IA
Table 2

Acceptance Criteria, NMT

Name Relative Retention Time Relative Response Factor (%)
IC

Azithromycin N-oxidea 0.29 0.43 0.5

3′-(N,N-Didemethyl)-3′-N-
formylazithromycinb,▲c▲
FF

(USP 1-May-2019) 0.37 1.7 0.5

▲Erythromycin A iminoetherd 0.42 1.0 0.5▲ (USP 1-May-2019)

3′-(N,N-
O

Didemethyl)azithromycin(am
inoazithromycin)e 0.43 1.0 0.5

Azithromycin related
compound Fc,f 0.51 3.8 0.5

Desosaminylazithromycing 0.54 1.0 0.3

3′-N-{[4-
(Acetylamino)phenyl]sulfonyl
}-3′,3′-
didemethylazithromycinh 0.55 12 0.15

N-Demethylazithromycini 0.61 1.0 0.7

▲Erythromycin A oximej 0.64 1.0 0.5▲ (USP 1-May-2019)

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 5/8
18/10/2020 USP-NF Azithromycin

Acceptance Criteria, NMT

Name Relative Retention Time Relative Response Factor (%)

Azithromycin C (3″-O-
demethylazithromycin)k 0.73 1.0 0.5

3′-De(dimethylamino)-3′-
oxoazithromycinl 0.76 1.5 0.5

3′-N-{[4-
(Acetylamino)phenyl]sulfonyl
}-3′-demethylazithromycinm 0.79 10 0.5

Azaerythromycin An 0.83 1.0 0.5

Azithromycin impurity Po 0.92 1.0 0.2

Azithromycin 1.0 — —

2-Desethyl-2-
propylazithromycinp 1.23 1.0 0.5

3′-N-Demethyl-3′-N-[(4-
methylphenyl)sulfonyl]azithr
omycinq 1.26 5 0.5

L
3-Deoxyazithromycin
(azithromycin B)r 1.31 1.0 1.0
IA
Any individual, unidenti ed —
impurity 1.0 0.2

Total impurities — — 3.0

IC

a 
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylazinoyl)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-
azacyclopentadecan-15-one.
b
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
FF

trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-formamido-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-
15-one.
c
  The system may resolve two rotamers. ▲▲ (USP 1-May-2019) The ▲limit is for the▲ (USP 1-May-2019) sum of the two rotamers. ▲▲

(USP 1-May-2019)
d
  (3R,4R,5S,6R,9R,10S,11S,12R,13S,15R,Z)-12-[[3,4,6-Trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-6-ethyl-4,5-dihydroxy-
O

10-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-3,5,9,11,13,15-hexamethyl-7,16-dioxa-2-
azabicyclo[11.2.1]hexadec-1-en-8-one.
e
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-amino-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-
one.
f  3′-N-Demethyl-3′-N-formylazithromycin; (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-(N-methyl)formamido-3,4,6-trideoxy-β-D-xylo-
hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
g  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
dimethylamino-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
h
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[N-(4-acetamidophenylsulfonyl)amino]-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-1-
oxa-6-azacyclopentadecan-15-one.
i  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-methylamino-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-
azacyclopentadecan-15-one.

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 6/8
18/10/2020 USP-NF Azithromycin
j
  (3R,4S,5S,6R,7R,9R,11S,12R,13S,14R,E)-6-[[3,4,6-Trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-14-ethyl-7,12,13-
trihydroxy-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-10-(hydroxyimino)-3,5,7,9,11,13-
hexamethyloxacyclotetradecan-2-one.
k
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-dimethylamino-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
l
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3,3-dimethyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-oxo-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
m  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[N-(4-acetamidophenylsulfonyl)-N-methylamino]-3,4,6-trideoxy-β-D-xylo-
hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
n
  9-Deoxo-9a-aza-9a-homoerythromycin A; 6-Demethylazithromycin.
o  Speci ed unidenti ed impurity.
p  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-propyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-
azacyclopentadecan-15-one.
q
  (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3-[N-(4-methylphenylsulfonyl)-N-methylamino]-3,4,6-trideoxy-β-D-xylo-
hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
r
  (2R,3R,4S,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-4,10-dihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-
one.

SPECIFIC TESTS
• OPTICAL ROTATION 〈781S〉, Procedures, Specific Rotation
Sample solution: 20 mg/mL in dehydrated alcohol
Acceptance criteria: −45° to −49°, at 20°

L
• CRYSTALLINITY 〈695〉: Meets the requirements, except where it is labeled as amorphous, most of the particles do not exhibit birefringence
and extinction positions
IA
• PH 〈791〉
Sample stock solution: 4 mg/mL in methanol
Sample solution: 2 mg/mL obtained by mixing equal volumes of Sample stock solution and water
Acceptance criteria: 9.0–11.0
• WATER DETERMINATION 〈921〉, Method I
IC

Where it is labeled as anhydrous: NMT 2.0%

Where it is labeled as the dihydrate: 4.0%–5.0%
Where it is labeled as the monohydrate: 1.8%–4.0%, except that it may be 4.0%–6.5% when the requirements of the Loss on Drying
test are met
FF

• LOSS ON DRYING: Where it is labeled as Azithromycin monohydrate and has a water content of 4.0%–6.5% (see Thermal Analysis 〈891〉)
[ NOTE— The quantity taken for this procedure may be adjusted, if necessary, for instrument sensitivity.]
Analysis: Determine the percentage of volatile substances by thermogravimetric analysis in an appropriately calibrated instrument,
using about 10 mg of Azithromycin. Heat the specimen at the rate of 10°/min between ambient temperature and 150° in an
atmosphere of nitrogen at a constant ow rate of about 35 mL/min. From the thermogram plot the derivatives of the loss on drying
O

(percentage loss/min), and identify the in ection points of the two weight loss steps at about 70° and 130°.
Acceptance criteria: NMT 4.5% between ambient temperature and the in ection point at about 70°, and 1.8%–2.6% between the
in ection point at about 70° and the in ection point at about 130°.

ADDITIONAL REQUIREMENTS
• PACKAGING AND STORAGE: Preserve in tight containers.
Change to read:
• LABELING: Label it to indicate whether it is anhydrous, the monohydrate, or the dihydrate. The amorphous form is so labeled. Where the
quantity of azithromycin is indicated in the labeling of any preparation containing Azithromycin, this shall be understood to be in terms
of anhydrous azithromycin (C38H72N2O12). ▲▲ (USP 1-May-2019)

Change to read:
• USP REFERENCE STANDARDS 〈11〉
USP Azaerythromycin A RS
9-Deoxo-9a-aza-9a-homoerythromycin A;
6-Demethylazithromycin.
C37H70N2O12 734.96
USP Azithromycin RS
USP Azithromycin Related Compound F RS

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 7/8
18/10/2020 USP-NF Azithromycin
3′-N-Demethyl-3′-N-formylazithromycin;
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3-(N-methyl)formamido-3,4,6-trideoxy-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-
one.
C38H70N2O13 762.97
▲
▲ (USP 1-May-2019)
USP Desosaminylazithromycin RS
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-dimethylamino-
β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one.
C30H58N2O9 590.79

Auxiliary Information- Please check for your question in the FAQs before contacting USP.

Topic/Question Contact Expert Committee

Azithromycin Marian Lydon FI2015 Food Ingredients 2015

Production Coordinator

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 43(3)

Page Information:

L
USP43-NF38 - 446
USP42-NF37 - 440
USP41-NF36 - 420
IA
Current DocID: GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US
IC
FF
O

https://online.uspnf.com/uspnf/document/1_GUID-34C99575-55AF-407A-8C43-79D17394E453_5_en-US?source=TOC 8/8